Stocks News

LAST PRICE
454.3050
TODAY'S CHANGE (%)
Trending Up0.7550 (0.1665%)

Bid / Lots
454.2100/ 3
Ask / Lots
454.4000/ 20
Open / Previous Close
454.9800 / 453.5500
Day Range
Low 452.6200
High 458.1400
52 Week Range
Low 341.9000
High 510.6350
Volume
471,489
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- DJ Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital, from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: VRTX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/VRTX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 04, 2024 11:36 ET (15:36 GMT)
- Goldman Sachs Adjusts Vertex Pharmaceuticals Price Target to $598 From $595, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: VRTX
  07:53 AM EDT, 10/04/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $600, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic...
- RBC Trims Price Target on Vertex Pharmaceuticals to $425 From $431, Keeps Sector Perform Rating, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: VRTX
  07:20 AM EDT, 10/04/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $325 to $600. (MT Newswires covers equity, commodity and eco...
Oct 1, 2024
- Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $518 From $576, Maintains Outperform Rating, from 10:14AM ET on Tuesday Oct 01, 2024 by MT Newswires
  10:14AM ET on Tuesday Oct 01, 2024 by MT Newswires
  Companies Mentioned: VRTX
  10:14 AM EDT, 10/01/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) has an average rating outperform and price targets ranging from $325 to $600, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic re...
- Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $474 From $462, Maintains Equalweight Rating, from 8:53AM ET on Tuesday Oct 01, 2024 by MT Newswires
  8:53AM ET on Tuesday Oct 01, 2024 by MT Newswires
  Companies Mentioned: VRTX
  08:53 AM EDT, 10/01/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $600, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic...

Today
- DJ Regeneron Pharma Is Maintained at Outperform by RBC Capital, from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: REGN
- DJ Biogen Is Maintained at Outperform by RBC Capital, from 5 hours ago by Dow Jones
  5 hours ago by Dow Jones
  Companies Mentioned: BIIB
- Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,294 From $1,292, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: REGN
- RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,260 From $1,252, Keeps Outperform Rating, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: REGN
- RBC Cuts Price Target on Biogen to $269 From $292, Keeps Outperform Rating, from 9 hours ago by MT Newswires
  9 hours ago by MT Newswires
  Companies Mentioned: BIIB
Yesterday
- Regeneron Pharmaceuticals Insider Sold Shares Worth $1,054,060, According to a Recent SEC Filing, from 23 hours ago by MT Newswires
  23 hours ago by MT Newswires
  Companies Mentioned: REGN
- DJ Biogen Is Maintained at Neutral by UBS, from 3:00PM ET on Thursday Oct 03, 2024 by Dow Jones
  3:00PM ET on Thursday Oct 03, 2024 by Dow Jones
  Companies Mentioned: BIIB
Oct 2, 2024
- IQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI(TM), from 9:00AM ET on Wednesday Oct 02, 2024 by Dow Jones
  9:00AM ET on Wednesday Oct 02, 2024 by Dow Jones
  Companies Mentioned: IQV
Sep 27, 2024
- S&P 500 Extends Winning Streak to Third Week as Materials Sector Climbs, from 4:55PM ET on Friday Sep 27, 2024 by MT Newswires
  4:55PM ET on Friday Sep 27, 2024 by MT Newswires
  Companies Mentioned: FCX, REGN, WYNN
- DJ Regeneron, Sanofi Get FDA OK of Dupixent for COPD -- Update, from 1:05PM ET on Friday Sep 27, 2024 by Dow Jones
  1:05PM ET on Friday Sep 27, 2024 by Dow Jones
  Companies Mentioned: REGN, SNY

Vertex Pharmaceuticals Inc
NASDAQ:VRTXUnited States

Search Criteria

Today

DJ Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital, from 4 hours ago by Dow Jones

Goldman Sachs Adjusts Vertex Pharmaceuticals Price Target to $598 From $595, from 8 hours ago by MT Newswires

RBC Trims Price Target on Vertex Pharmaceuticals to $425 From $431, Keeps Sector Perform Rating, from 8 hours ago by MT Newswires

Oct 1, 2024

Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $518 From $576, Maintains Outperform Rating, from 10:14AM ET on Tuesday Oct 01, 2024 by MT Newswires

Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $474 From $462, Maintains Equalweight Rating, from 8:53AM ET on Tuesday Oct 01, 2024 by MT Newswires

Peers Headlines

Today

DJ Regeneron Pharma Is Maintained at Outperform by RBC Capital, from 4 hours ago by Dow Jones

DJ Biogen Is Maintained at Outperform by RBC Capital, from 5 hours ago by Dow Jones

Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,294 From $1,292, from 8 hours ago by MT Newswires

RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,260 From $1,252, Keeps Outperform Rating, from 8 hours ago by MT Newswires

RBC Cuts Price Target on Biogen to $269 From $292, Keeps Outperform Rating, from 9 hours ago by MT Newswires

Yesterday

Regeneron Pharmaceuticals Insider Sold Shares Worth $1,054,060, According to a Recent SEC Filing, from 23 hours ago by MT Newswires

DJ Biogen Is Maintained at Neutral by UBS, from 3:00PM ET on Thursday Oct 03, 2024 by Dow Jones

Oct 2, 2024

IQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI(TM), from 9:00AM ET on Wednesday Oct 02, 2024 by Dow Jones

Sep 27, 2024

S&P 500 Extends Winning Streak to Third Week as Materials Sector Climbs, from 4:55PM ET on Friday Sep 27, 2024 by MT Newswires

DJ Regeneron, Sanofi Get FDA OK of Dupixent for COPD -- Update, from 1:05PM ET on Friday Sep 27, 2024 by Dow Jones